Multicenter, double blind, randomized controlled trial on the effects and safety of Compound Sanhuang Capsule for HIV/AIDS

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-08000064

Enrollment

Unknown

Registered

2008-03-05

Start date

2005-07-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS

Interventions

Compound Sanhuang Capsule group:6# po. tid. for 36 weeks

Small dosage control group:Small dosage 6# po. tid. for 36 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Patients with epidemic history and clinical manifestations of AIDS and with diagnosis confirmed by AIDS confirmatory test; (2) Aged between 18 and 60 years old, and no restriction on sex; (3) CD4+ >250cells/ul, <500cells/ul; (4) Volunteered to accept treatment of the drugs; (5) Did not received any other anti-AIDS agents within the 6 months before the trial.

Exclusion criteria

Exclusion criteria: (1) Patients in acute infection period; (2) In treatment of other aiti-AIDS drugs; (3) Severe psychotic or neurological diseases; (4) History of anti-virus treatment in the latest 3 months; (5) Severe hepatic and renal dysfunction (transaminase >4*normal range of creatine >normal range); (6) Severe opportunistic infection or tumor; (7) Allergic constitution; (8) Pregnant or breast-feeding females; (9) History of alcoholism and could not cease it.

Design outcomes

Primary

Measure	Time frame
HIV virus load;	—

Secondary

Measure	Time frame
CD4 T lymphocyte;	—

Countries

China

Contacts

Public ContactHao Wu

wuhd@public.bta.net.cn+86 010 63053963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026